Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
27 Julho 2023 - 5:30PM
Cellectis to Report Second Quarter 2023 Financial Results on August
3, 2023
Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ:
CLLS), a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today announced that it will report financial results
for the second quarter ended June 30, 2023 on Thursday, August 3,
2023 after the close of the US market.
The announcement will be followed by an investor
conference call and webcast on Friday, August 4, 2023 at 8:00 am ET
/ 2:00 pm CET. The call will include the Company’s second quarter
results and an update on business activities. Details for the call
are as follows:
Dial in information:
Domestic: 1-877-451-6152
International: 1-201-389-0879
Conference ID: 13739252
Webcast
Link: https://viavid.webcasts.com/starthere.jsp?ei=1619596&tp_key=40e9fac8fc
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
23 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “expect,” “plan,” “could” and “will,” or the negative
of these and similar expressions. These forward-looking statements,
which are based on our management’s current expectations and
assumptions and on information currently available to management.
These forward-looking statements are made in light of information
currently available to us and are subject to numerous risks and
uncertainties, including with respect to the numerous risks
associated with biopharmaceutical product candidate development.
With respect to our cash runway, our operating plans, including
product development plans, may change as a result of various
factors, including factors currently unknown to us. Furthermore,
many other important factors, including those described in our
Annual Report on Form 20-F and the financial report (including the
management report) for the year ended December 31, 2022 and
subsequent filings Cellectis makes with the Securities Exchange
Commission from time to time, as well as other known and unknown
risks and uncertainties may adversely affect such forward-looking
statements and cause our actual results, performance or
achievements to be materially different from those expressed or
implied by the forward-looking statements. Except as required by
law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results
could differ materially from those anticipated in the
forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14
33, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
- Q2 2023 earnings call announcement
Cellectis Nom Eo 05 (EU:ALCLS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024